Upstart Holdings Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Upstart Holdings Inc trades at $22.65 (market cap $2.32B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Upstart Holdings Inc is the larger of the two by market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Upstart Holdings Inc for 39 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| UPST | VIR | |
|---|---|---|
Market Cap | $2.32B | $1.80B |
Volume | 3,123,987 | 1,782,836 |
Sector | Financials | Health |
52-Week High | $52.74 | $11.78 |
52-Week Low | $22.74 | $5.12 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $3.85B | $1.36B |
Signals from Pluang's Aura AI — not financial advice
UPST trades at $22.74, down 4.25% on the day, with a bearish technical signal and recent earnings misses. Revenue grew to $1.02B in 2025, turning profitable with $53.60M net income, but cash flow from operations remains negative. The stock is trading well below the consensus price target of $38.13, with analysts divided between Buy and Hold ratings.
The outlook is mixed: strong revenue growth and profitability improvements offer upside potential, but persistent cash burn, high debt levels, and sensitivity to credit markets pose significant risks. Investor sentiment is cautious amid recent price declines and sector-wide pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →